Research
Hormonal
GLP-1/Apelin hybrid peptides (ELA, ELA-Lys12, ELA-Lys38) significantly improve glucose tolerance and insulin secretion in both lean and high-fat-fed mice, with effects lasting up to 21 hours for acylated forms.
These hybrid peptides effectively lower blood glucose levels in mice for up to 21 hours, outperforming single-target approaches in duration. This suggests potential for less frequent dosing in diabetes management, though human trials are required.
ModerateSupportsMEDIUM confidence
All peptides significantly improved glucose tolerance in lean and HFF mice, indicating enhanced insulin action and glycaemic control. Acylation extended the duration of glucose-lowering benefits up to 21 h.
Why this rating
Study is conducted in mice, including a high-fat-fed model, but not in humans.
Source
Unimolecular <scp>GLP</scp> ‐1/Apelin Hybrid Peptides Cause Prominent Appetite Suppression, as Well as Enhancing Insulin Secretion, Beta‐Cell Survival and Glycaemic Regulation
Ananyaa Sridhar et al. · Diabetes Obesity and Metabolism · 2026
DOI 10.1111/dom.70647
mechanism_only
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Unimolecular GLP-1/Apelin hybrid peptides (specifically ELA, ELA-Lys12, and ELA-Lys38) cause prominent appetite suppression in mice without inducing malaise, with effects lasting up to 42 hours for the base peptide and 63 hours for acylated forms.Moderate
- GLP-1/Apelin hybrid peptides enhance beta-cell proliferation and protect against cytokine-induced apoptosis, contributing to beta-cell survival.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →